Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Infracapital on the acquisition of Falbygdens Energi
Mandate

Vinge advises Infracapital on the acquisition of Falbygdens Energi

December 02, 2013

Vinge is advising Infracapital, a leading European infrastructure investor, managed by M&G Investment Management, the European investment management arm of Prudential plc in connection with the acquisition of Falbygdens Energi AB from Göteborg Energi AB.

Falbygdens Energi AB operates primarily within the Swedish municipality of Falköping. The business operations comprise mainly of the production and distribution of district heating and the distribution of electricity in the area. The electricity distribution network comprises 522 kilometres of overhead lines and 1,690 kilometres of underground cables. FEAB also operates a broadband business in the municipality.

Johan Göthberg was the responsible partner together with associates Matthias Pannier, Lisa Antman, Joel Zetterström, Gabriel Westin, Emma Kero Ljungberg and counsel Robert Deli. Partner Thomas Sjöberg and associate Sofia Ekdahl are advising on real estate and environmental questions.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024